Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Dec;15(12):2037-44.
doi: 10.1093/ntr/ntt097. Epub 2013 Jul 19.

A randomized phase II clinical trial of high-dose nicotine patch therapy for smokeless tobacco users

Affiliations
Clinical Trial

A randomized phase II clinical trial of high-dose nicotine patch therapy for smokeless tobacco users

Jon O Ebbert et al. Nicotine Tob Res. 2013 Dec.

Abstract

Introduction: Nicotine patch therapy has not been shown to be efficacious for increasing long-term (≥6 months) tobacco abstinence rates among smokeless tobacco (ST) users. Higher doses of nicotine patch therapy may be needed to increase tobacco abstinence rates in this population of tobacco users.

Methods: We randomized ST users who used ≥3 cans/pouches per week to either 8 weeks of high-dose nicotine patch therapy (42mg/day) or matching placebo patch. Subjects were followed for 6 months after randomization.

Results: Fifty-two subjects were randomized. Compared with placebo, high-dose nicotine patch therapy was associated with significantly higher prolonged tobacco abstinence at end-of-treatment (44% vs. 22%, odds ratio [OR] = 2.7, p = .050) and 3 months (40% vs. 19%, OR = 2.9, p = .047). High-dose nicotine patch therapy was associated with significant weight gain attenuation among tobacco abstinence subjects at 3 months (p = .013) and 6 months (p = .018). Compared with placebo, high-dose nicotine patch therapy was associated with nonsignificantly lower nicotine withdrawal scores. Adverse events were not significantly increased with high-dose nicotine patch therapy.

Conclusions: High-dose nicotine patch therapy is safe and increases short-term tobacco abstinence rates among ST users who use ≥3 cans/pouches per week. High-dose nicotine patch therapy is associated with significant long-term attenuation of weight gain. Future studies to investigate the long-term efficacy of high-dose nicotine patch therapy and the comparative efficacy of this approach compared with standard nicotine patch doses for ST users seems warranted.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CONSORT diagram.
Figure 2.
Figure 2.
Composite nicotine withdrawal of smokeless tobacco users in a randomized clinical trial of high-dose nicotine patch therapy.

References

    1. Aubin H. J., Farley A., Lycett D., Lahmek P., Aveyard P. (2012). Weight gain in smokers after quitting cigarettes: Meta-analysis. British Medical Journal, 345, e4439 doi:10.1136/bmj.e4439 - PMC - PubMed
    1. Benowitz N. L., Ahijevych K., Hall S., Hansson A., Henningfield J., Hurt R. D. … Velicer W. (2002). Biochemical verification of tobacco use and cessation. Nicotine & Tobacco Research, 4, 149–159 doi:10.1080/ 14622200210123581 - PubMed
    1. Benowitz N. L., Porchet H., Sheiner L., Jacob P., III (1988). Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum. Clinical Pharmacology and Therapeutics, 44, 23–28 doi:10.1038/clpt.1988.107 - PubMed
    1. Clark M. M., Decker P. A., Offord K. P., Patten C. A., Vickers K. S., Croghan I. T. … Dale L. C. (2004). Weight concerns among male smokers. Addictive Behaviors, 29, 1637–1641 doi:10.1016/j.addbeh.2004.02.034 - PubMed
    1. Dale L. C., Ebbert J. O., Glover E. D., Croghan I. T., Schroeder D. R., Severson H. H., Hurt R. D. (2007). Bupropion SR for the treatment of smokeless tobacco use. Drug and Alcohol Dependence, 90, 56–63 doi:10.1016/j.drugalcdep.2007.02.008 - PMC - PubMed

Publication types